SAVA
Filana Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.32
+2.33%Sep 18, 2026, 20:17 UTC
Filana Therapeutics, Inc. received a Nasdaq notice dated September 17, 2026 that it no longer complies with the minimum bid price requirement under Listing Rule 5550(a)(2), giving it until March 16, 2027 to regain compliance.
Jul 29, 2026, 12:00 UTC
Filana Therapeutics reported financial results for the second quarter ended June 30, 2026.
Source:Jun 15, 2026, 00:00 UTC
Filana Therapeutics, Inc. elected Richard J. Barry, Pierre Gravier, and Claude Nicaise as directors effective June 11, 2026.